Synlogic, Inc. Overview
Pro stress-test →Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. The biopharmaceutical company engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. The company represents a pioneering attempt to use genetically engineered living probiotics as novel therapeutic agents.
Strategic Profile
Pro stress-test →The Company focuses on rare metabolic diseases, with its lead program, labafenogene marselecobac (SYNB1934), currently being studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU). The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Strategic partnerships with major pharma and biotech players provide credibility and resources, though the company experienced significant setbacks with a 90%+ workforce reduction in 2024.
Competitive Landscape
Pro stress-test →Synlogic is based in Winchester, Massachusetts, positioning it within a major biotech hub. Direct competitors in synthetic biology therapeutics are limited, with Ginkgo Bioworks being a key collaborative partner rather than competitor. The company competes broadly with traditional PKU treatments and other rare metabolic disease therapies from larger pharma. Its micro-cap status and clinical setbacks have eroded competitive positioning.
Industry Context
Synlogic, Inc. operates in Biotechnology - Synthetic Biology / Rare Metabolic Diseases.
Key facts
Founded: 2013 · Headquarters: Winchester, MA · Employees: 1 · Revenue: Minimal (collaboration/grant-dependent) · Market cap: $7.78M